文献速递白血病

siRNA沉默突变NPM1通过逆转KAT7/p300介导的组蛋白乙酰化抑制急性髓系白血病

Small interfering RNA-mediated silencing of mutant NPM1 suppresses acute myeloid leukemia via reversing KAT7 and p300-mediated histone acetylation.
PubMed 文献 · Leukemia · 2026-06-26

本研究开发了一种等位基因特异性siRNA,选择性沉默突变NPM1(NPM1c)而保留野生型NPM1功能。体外实验表明该siRNA抑制NPM1突变AML细胞增殖并促进髓系分化;体内通过脂质纳米颗粒(LNP)递送化学优化siNPM1c可显著减少白血病发生,并增强menin抑制剂revumenib的疗效及克服其耐药。机制上NPM1c招募KAT7和p300驱动致癌转录和开放染色质状态,靶向NPM1c可破坏该复合物并逆转表观遗传景观。

要点

  • 等位基因特异性siRNA可选择性沉默NPM1c而不影响野生型NPM1。
  • LNP递送siNPM1c在体内减少白血病发生并增强revumenib疗效、克服耐药。
  • NPM1c通过招募KAT7和p300驱动致癌乙酰化组和开放染色质。

核心结论

  • 沉默NPM1c通过 dismantling KAT7/p300依赖的致病性乙酰化组有效抑制AML。
  • LNP递送siNPM1c可作为单药或联合menin抑制的潜在治疗策略。

研究设计与样本

  • 研究开发了等位基因特异性siRNA,并在体外NPM1突变AML细胞及体内模型中评估其效果。
  • 体内采用脂质纳米颗粒(LNP)系统递送化学优化的siNPM1c。

主要发现

  • siNPM1c在体外抑制NPM1突变AML细胞增殖并促进髓系分化。
  • LNP递送siNPM1c在体内显著减少白血病发生。
  • siNPM1c增强menin抑制剂revumenib的疗效并克服其耐药。
  • NPM1c招募KAT7和p300驱动致癌转录,KAT7招募对复合物滞留染色质至关重要。
  • 靶向NPM1c破坏该相互作用,逆转致癌表观遗传景观并抑制转录。

临床怎么用

  • LNP递送siNPM1c可能作为NPM1突变AML的靶向治疗策略。
  • siNPM1c与menin抑制剂revumenib联用可能增强疗效并克服耐药。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

NPM1 mutation (NPM1c)-driven acute myeloid leukemia (AML) is characterized by the sequestration of nuclear proteins and chromatin hijacking. Current treatment strategies targeting NPM1c AML are often indirect, which might lead to toxicity and resistance. In this study, we developed an allele-specific siRNA that selectively silences NPM1c while preserving the function of wild-type NPM1. This approach inhibited proliferation and promoted myeloid differentiation in NPM1-mutated AML cells in vitro. Notably, the systemic delivery of chemically optimized siNPM1c via lipid nanoparticles (LNPs) significantly reduced leukemogenesis, and enhanced the therapeutic efficacy of the menin inhibitor revumenib and overcame its resistance in vivo. Mechanistically, NPM1c recruits KAT7 and p300, driving leukemogenic transcription and establishing a pathogenic acetylome and open chromatin state. KAT7 recruitment is crucial for the retention of this complex on chromatin. Targeting NPM1c with siRNA disrupts this interaction, reverses the oncogenic epigenetic landscape, and suppresses transcription. Our findings demonstrate that silencing NPM1c effectively suppresses AML by dismantling a pathogenic KAT7/p300-dependent acetylome, highlighting the potential of LNP‑delivered siNPM1c as a promising therapeutic strategy, either as a monotherapy or in combination with menin inhibition.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Hou Y, Xing Y, Chen C, et al. Small interfering RNA-mediated silencing of mutant NPM1 suppresses acute myeloid leukemia via reversing KAT7 and p300-mediated histone acetylation. Leukemia. 2026. PMID: 42362805. doi:10.1038/s41375-026-03014-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。